DNA encoding IGFBP-4
US6004775A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 20, 1993 |
| Grant date | Dec 21, 1999 |
| Priority date | — |
| Expiry date | Aug 20, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An insulin-like growth factor binding protein is isolated from rat serum and partially sequenced. Using nucleotide probes based upon the amino terminal sequence of the isolated protein, the complete sequence for the 233-residue rat protein, termed IGFBP-4, is deduced, and the homologous 237-residue sequence of the human protein is separately deduced. These proteins are useful in the inhibition of cell differentiation and/or proliferation requiring IGFs and are particularly useful in combating breast cancers. Antibodies to the proteins may be employed in diagnostic assays, in purification of the protein and in the modulation of bone growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.